Positive Regulatory Outcome – Enhanced study design “This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the summer months. We can now see the finish line and we hope that the next couple of months develop as planned so that we can […]
In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy designation MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the US Food and Drug Administration (FDA) has […]
CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma. Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize […]
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present scientific posters at the following conferences in November 2019. The Huntington Study Group 2019 Annual Meeting 7 – 9 November 2019, Sacramento, California, USA IXICO will present a poster entitled “A Fully […]
-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company -S.T.U. GmbH is the owner of market leading brand Hemplix™ October 29, 2019 Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer […]
